Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115566 · ClinicalTrials.gov registry record
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
A clinical trial of Hidradenitis Suppurativa, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT04115566: Recruiting study of Hidradenitis Suppurativa, sponsored by University of California, San Francisco.
NCT04115566 is a study of Hidradenitis Suppurativa that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 3,000 participants, above the 540-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (456% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04115566, a study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.
Primary Outcome
The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.
Conditions Studied
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2035-05-01 |
What NCT04115566 shows while recruiting
NCT04115566 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 540-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (456% higher).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 0 interventions.
NCT04115566 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04115566 about?
NCT04115566 is a clinical study titled "Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository". Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characte...
What is the current status of trial NCT04115566?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2020-08-01. Estimated completion is 2035-05-01.
What conditions does trial NCT04115566 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
Who is sponsoring clinical trial NCT04115566?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04115566 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04115566's enrollment target sits among peer trials
3,000 2nd of 52 the highest of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI